In a significant shift in policy, the High Authority of Health (HAS) in France has published new recommendations that effectively mark the end of the psychotherapeutic approach of psychoanalysis for treating autism. The HAS, after a thorough review of scientific literature, found no evidence demonstrating the effectiveness of psychoanalysis in autism treatment, relegating it to the ranks of 'not recommended' interventions. This decision comes after years of debate and criticism regarding the use of psychoanalysis, which many in the medical community have long viewed as outdated and ineffective.

The report highlights that alternative methods, such as neurofeedback and other therapies, have demonstrated efficacy and are now endorsed as viable treatment options. This marks a significant change for French health authorities, which have historically been slow to adapt to emerging evidence and methodologies used in autism treatment globally. The dismissal of psychoanalysis aligns France closer to practices in other countries where similar conclusions were made years ago, reflecting a growing recognition of the need for evidence-based approaches in healthcare.

Furthermore, this change could have profound implications for patients and practitioners alike. By eliminating psychoanalysis from recommended autism treatments, the HAS paves the way for a more scientifically informed approach that prioritizes the needs of individuals with autism. This may also lead to greater research investments into alternative therapies and a reevaluation of training for professionals working in this field, aiming to provide better support and outcomes for those affected by autism.